Comparison of the BOPPPS Model and Traditional Instructional Method in Medicinal Chemistry Education

August 11, 2026 updated by: Liang Qi, Jiangsu Medical College

Comparison of the BOPPPS Model and Traditional Instructional Method in Medicinal Chemistry Education for Pharmacy Students

This study aims to compare the teaching effect of the BOPPPS teaching model and the traditional lecture-based teaching method in Medicinal Chemistry courses for pharmacy students. Two groups of students receiving different teaching strategies will be included in this retrospective controlled study. The primary evaluation indicators include students' final examination scores, and secondary indicators cover classroom learning engagement and student satisfaction questionnaires. The overall objective is to explore whether the BOPPPS model can improve students' learning performance and learning experience in Medicinal Chemistry teaching. No human clinical intervention or invasive testing is involved in this educational research.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This educational controlled study focuses on the teaching reform of Medicinal Chemistry, a core compulsory course for pharmacy majors in higher vocational colleges. Traditional lecture-centered teaching is widely adopted in vocational pharmacy teaching, which often leads to insufficient student participation, weak initiative in classroom interaction, and unsatisfactory learning efficiency for complex pharmaceutical chemical structures and synthetic reactions.The BOPPPS teaching model divides each class into six standardized links: Bridge-in, Objectives, Pre-assessment, Participatory learning, Post-assessment, Summary. This student-centered teaching design strengthens classroom interaction and targeted detection of learning effects. At present, there is limited comparative research on the application of this model in Medicinal Chemistry teaching for vocational pharmacy students.This retrospective controlled research collects historical teaching data of two student groups receiving different teaching modes. The research intends to systematically analyze the differences in learning outcomes between the two teaching strategies, so as to provide practical teaching reform references for Medicinal Chemistry courses in vocational pharmacy education. This study only adopts routine classroom teaching and anonymous questionnaire surveys, without any clinical medical intervention, blood sampling or physical examination on participants. All student data are anonymized to protect personal privacy. Article 32 of the Notice on Printing and Distributing the Measures for Ethical Review of Life Science and Medical Research Involving Humans, jointly issued by the National Health Commission of China, the Ministry of Education, the Ministry of Science and Technology, and the National Administration of Traditional Chinese Medicine, stipulates that "Life science and medical research involving humans that uses human information, data or biological samples may be exempt from ethical review if such research falls under the circumstances specified below, causes no physical harm to human participants, and does not involve sensitive personal information or commercial interests." As a study focusing on teaching effectiveness, the present research qualifies for an exemption from ethical review pursuant to this provision.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
60

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Jiangsu
      • Yancheng, Jiangsu, China, 224005
        • Jiangsu Medical College

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Full-time pharmacy students without previous Medicinal Chemistry learning experience
  • Complete all academic assessments and anonymous questionnaire surveys

Exclusion Criteria:

  • Classroom attendance rate less than 80%
  • Students who are unwilling to provide relevant data for this educational study or miss the final exam

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Experimental Group (BOPPPS Teaching Model)
Pharmacy students receive Medicinal Chemistry courses adopting the complete six-link BOPPPS teaching design, including Bridge-in, Objectives, Pre-assessment, Participatory learning, Post-assessment and Summary. Interactive classroom activities and in-class tests are arranged in each lesson.
Other: BOPPPS six-stage teaching intervention
Medicinal Chemistry teaching based on BOPPPS model, consisting of Bridge-in, Objectives, Pre-assessment, Participatory learning, Post-assessment and Summary sessions with abundant classroom interaction.
Active Comparator: Control Group (Traditional Lecture Teaching)
Pharmacy students receive teacher-centered traditional lecture-based Medicinal Chemistry teaching. The teacher explains knowledge points directly, with few classroom interactive sessions.
Other: Conventional lecture-based teaching intervention
Traditional teacher-centered lecture teaching for Medicinal Chemistry, mainly knowledge explanation, without segmented pre-assessment and post-assessment arrangements.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Final examination scores of Medicinal Chemistry
Time Frame: At the completion of the teaching intervention, up to 1 week
Final exam scores to evaluate students' mastery of professional knowledge of Medicinal Chemistry. Scores range from 0 to 100. Higher scores indicate better academic performance.
At the completion of the teaching intervention, up to 1 week

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Student teaching satisfaction score
Time Frame: At the completion of the teaching intervention, up to 1 week
Score from an anonymous questionnaire evaluating students' satisfaction with the classroom teaching model. The total score ranges from 1 to 5. Higher scores indicate higher satisfaction.
At the completion of the teaching intervention, up to 1 week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Jiangsu Medical College

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Liang Qi, PhD, Jiangsu Medical College

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
September 15, 2025

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 6, 2026

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
January 8, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 6, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 11, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 17, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 17, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 11, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • JiangsuMC-20260806
  • 2025JGYB272 (Other Grant/Funding Number: Jiangsu Society of Higher Education)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

De-identified individual participant-level data supporting this study, together with a complete data dictionary, will be accessible to qualified external researchers upon reasonable written request after the primary manuscript is published. Data release is conditional on institutional and regulatory privacy authorization. All formal data access requests should be submitted to the corresponding author for evaluation and review. No identifiable personal information will be included in shared datasets to protect student privacy.

IPD Sharing Time Frame

De-identified individual participant data and supporting documents will be available to qualified researchers indefinitely after the publication of the primary study manuscript.

IPD Sharing Access Criteria

Data and supporting documents are available only to qualified academic researchers with legitimate educational research objectives. All applicants shall submit a formal written research request to the corresponding author. Data release is subject to institutional privacy and regulatory authorization. Applicants must provide a clear research plan and agree to use the shared de-identified data solely for independent academic research, without attempting to re-identify participants or share datasets with third parties.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings